Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer

NCT04093648 is registered in ClinicalTrials.gov with Baylor College of Medicine as lead sponsor.

NCT NCT04093648
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04093648 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
T Cells co- Expressing a Second Generation Glypican 3-specific Chimeric Antigen Receptor With Cytokines Interleukin-21 and 15 as Immunotherapy for Patients With Liver Cancer
Lead sponsor
Baylor College of Medicine
Phase
Phase 1
Overall status
Withdrawn
Start date
January 31, 2020
Completion date
January 31, 2038
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatoblastoma, hepatocellular carcinoma